Jason Sean O'Connor

US Patent:

20090143732, Jun 4, 2009

Filed:

Nov 29, 2007

Appl. No.:

11/947117

Inventors:

Jason B. O'Connor - South Boston MA, US
Luis Malave - Reading MA, US

Assignee:

INSULET CORPORATION - Bedford MA

International Classification:

A61M 5/142

US Classification:

604151

Abstract:

A prefilled syringe may be interfaced with and used to fill an infusion pump with therapeutic liquid. The dispensing end of the prefilled syringe may be coupled (either directly or indirectly using a syringe cap) to a syringe coupling region of the infusion pump, for example, using a threaded engagement or snap fit engagement. As the dispensing end of the prefilled syringe is coupled to the syringe coupling region of the pump housing, a needle passes through the pump housing and/or a needle passage region of the dispensing end such that the prefilled syringe is fluidly coupled to a reservoir in the pump. In various embodiments, the needle may be located in the syringe coupling region or in a syringe cap coupled to the dispensing end of the prefilled syringe.

US Patent:

20220293234, Sep 15, 2022

Filed:

Mar 10, 2022

Appl. No.:

17/691829

Inventors:

- Acton MA, US
Eric BENJAMIN - Cambridge MA, US
Jason O'CONNOR - Acton MA, US
Yibin ZHENG - Hartland WI, US

International Classification:

G16H 20/13
A61M 5/172

Abstract:

The exemplary embodiments may modify a glucose cost component of the cost function of the control loop of an insulin delivery device to compensate for persistent positive low level glucose excursions relative to a target glucose level. The exemplary embodiments may enable use of different glucose cost component functions for different glucose levels of the user. These glucose cost component functions may be employed in piecewise fashion with a different piece being applied for each respective range of glucose level values for the user. The final glucose cost function for calculating the glucose cost component may be a weighted combination of a piecewise glucose cost function and a weighted standard cost function (such as a quadratic function). The weights may reflect the magnitude and/or persistence of glucose excursions relative to a target glucose level.

US Patent:

20220273927, Sep 1, 2022

Filed:

Feb 10, 2022

Appl. No.:

17/669106

Inventors:

- Acton MA, US
Steven CARDINALI - Tewksbury MA, US
Jason O'CONNOR - Acton MA, US

International Classification:

A61M 37/00
A61M 5/142

Abstract:

Embodiments of the present disclosure relate to techniques, processes, devices or systems including a floating microneedle assembly decoupled from the device and protected by a pump housing. In one approach, a wearable drug delivery device may include a pump housing including a base attachable to a user, and a microneedle assembly coupled to a cannula. The microneedle assembly may be operable to deliver a liquid drug to the user, wherein the microneedle assembly comprises a carrier positioned proximate an opening of the base, and wherein the carrier comprises a plurality of microneedles operable to extend through the opening of the base to penetrate a skin of the user.

US Patent:

20220249773, Aug 11, 2022

Filed:

Feb 4, 2022

Appl. No.:

17/665165

Inventors:

- Acton MA, US
Joon Bok LEE - Acton MA, US
Jason O'CONNOR - Acton MA, US

International Classification:

A61M 5/172
G16H 20/17
A61B 5/145
A61M 5/142

Abstract:

Disclosed are techniques, a system and devices that enable the setting of an upper boundary constraint that may be a multiple of a total daily dosage setting for a liquid drug being administered to a user to control a condition, such as type 1 or type 2 diabetes mellitus. An automatic drug delivery algorithm may be configured to obtain a glucose control metric. A controller executing the automatic drug delivery algorithm may ascertain, based on the glucose control metric, an upper boundary constraint for the liquid drug that limits an amount of a dose of the liquid drug that may be delivered by the automatic drug delivery system or components thereof.

US Patent:

20220240847, Aug 4, 2022

Filed:

Jan 24, 2022

Appl. No.:

17/582374

Inventors:

- Acton MA, US
Jason O'CONNOR - Acton MA, US
Yibin ZHENG - Hartland WI, US
Ashutosh ZADE - San Diego CA, US

International Classification:

A61B 5/00
A61B 5/145
A61K 38/22
G16H 20/17
G16H 40/67

Abstract:

Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.

US Patent:

20220241504, Aug 4, 2022

Filed:

Jan 24, 2022

Appl. No.:

17/582349

Inventors:

- Acton MA, US
Jason O'CONNOR - Acton MA, US
Yibin ZHENG - Hartland WI, US
Ashutosh ZADE - San Diego CA, US

International Classification:

A61M 5/172
G16H 20/17

Abstract:

Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.

US Patent:

20220226576, Jul 21, 2022

Filed:

Apr 7, 2022

Appl. No.:

17/715589

Inventors:

- Acton MA, US
Joon Bok LEE - Acton MA, US
Ashutosh ZADE - San Diego CA, US
Jason O'CONNOR - Acton MA, US

International Classification:

A61M 5/172
G06F 17/17

Abstract:

Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.

US Patent:

20220199215, Jun 23, 2022

Filed:

Dec 17, 2021

Appl. No.:

17/555040

Inventors:

- Acton MA, US
Daniel MURRAY - Sudbury MA, US
Joon Bok LEE - Acton MA, US
Jason O'CONNOR - Acton MA, US

International Classification:

G16H 20/13
G08B 21/24
G08B 25/00
G08B 5/22
G06F 3/04842

Abstract:

Exemplary embodiments may enable a user to schedule medicament bolus deliveries, such as insulin boluses, for future dates and times. The exemplary embodiments may provide the ability to delay a scheduled medicament bolus delivery by short periods of time. The user may reschedule a scheduled medicament bolus delivery by entering a new date and/or time for the medicament bolus delivery. Still further, a user may cancel a scheduled medicament bolus delivery. In addition, exemplary embodiments may enable multiple medicament bolus deliveries to be viewed and managed.